Alto Neuroscience, Inc. (ANRO) — 10-Q Filings

10-Q Filings (6)

• Alto Narrows Quarterly Loss, Boosts Capital with $49.9M Private Placement — Nov 12, 2025 Risk: medium
  Alto Neuroscience, Inc. (ANRO) reported a net loss of $14.181 million for the three months ended September 30, 2025, an improvement from the $16.783 million net
• Alto Neuroscience Losses Widen Amid Stable R&D Spend — Aug 13, 2025 Risk: high
  Alto Neuroscience, Inc. reported a net loss of $17.706 million for the three months ended June 30, 2025, an increase from $16.030 million for the same period in
• Alto Neuroscience Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its finan
• Alto Neuroscience 10-Q Filing: Q3 2024 Update — Nov 12, 2024 Risk: medium
  Alto Neuroscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its clinical
• Alto Neuroscience Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Alto Neuroscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on pharmaceutical preparations, reported financial data for the
• Alto Neuroscience Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Alto Neuroscience, Inc. (ANRO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Alto Neuroscience, Inc. filed a 10-Q report for the period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX